Syrosingopine

Syrosingopine (Su 3118) is an orally active lactate transporters (MCT1/MCT4) dual inhibitor, which can reduce glycolysis and induce synthetic lethality in cancer cells when combine with metformin. Syrosingopine shows anti-hypertensive activity by depleting peripheral stores of norepinephrine[1][2].

Product Specifications

CAS Number

[84-36-6]

Product Name Alternative

Su 3118

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Monocarboxylate Transporter

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/syrosingopine.html

Concentration

10mM

Purity

99.52

Solubility

DMSO : 62.5 mg/mL (ultrasonic)

Smiles

[H][C@@]12C(NC3=C4C=CC(OC)=C3)=C4CCN1C[C@]5(C[C@@H](OC(C6=CC(OC)=C(OC(OCC)=O)C(OC)=C6)=O)[C@H](OC)[C@@H](C(OC)=O)[C@]5(C2)[H])[H]

Molecular Formula

C35H42N2O11

Molecular Weight

666.71

Precautions

H302, H315, H319, H335

References & Citations

[1]Benjamin D, et al. Dual Inhibition of the Lactate Transporters MCT1 and MCT4 Is Synthetic Lethal with Metformin due to NAD+ Depletion in Cancer Cells. Cell Rep. 2018 Dec 11;25 (11) :3047-3058.e4. |[2]Lefèvre-Borg F, et al. Role of the sympathetic nervous system in blood pressure maintenance and in the antihypertensive effects of calcium antagonists in spontaneously hypertensive rats. Hypertension. 1988 Apr;11 (4) :360-70.